| P2093 | author name string | Jeroen P Kooman | |
| | Frank M van der Sande | |
| | Karel M L Leunissen | |
| P2860 | cites work | Prediction of Coronary Heart Disease Using Risk Factor Categories | Q22241923 |
| | Atherosclerosis — An Inflammatory Disease | Q26776972 |
| | Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs | Q28184413 |
| | Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men | Q29619308 |
| | Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group | Q34064191 |
| | Need to test the arterial inflammation hypothesis | Q34136541 |
| | C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease | Q34311841 |
| | IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly | Q34404831 |
| | Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence | Q35203190 |
| | C-reactive protein in end-stage renal disease: are there reasons to measure it? | Q35997686 |
| | C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women | Q40608305 |
| | A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis | Q42524986 |
| | Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events | Q43656468 |
| | Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein | Q43984480 |
| | Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients | Q44015510 |
| | Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus | Q44082735 |
| | Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events | Q44216708 |
| | C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle | Q44382946 |
| | Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study | Q44433022 |
| | Associations between circulating inflammatory markers and residual renal function in CRF patients | Q44459462 |
| | Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular Health study). | Q44530603 |
| | Distribution and correlates of C-reactive protein concentrations among adult US women | Q44717096 |
| | C-reactive protein levels and outcomes after statin therapy | Q45213511 |
| | Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis | Q46610834 |
| | C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis | Q47304955 |
| | Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. | Q48015051 |
| | Inflammation in cardiovascular disease: cart, horse, or both? | Q48018364 |
| | Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. | Q50866439 |
| | C-reactive protein upregulates complement-inhibitory factors in endothelial cells. | Q51033463 |
| | Novel inflammatory markers of coronary risk: theory versus practice. | Q54332281 |
| | CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease | Q57154282 |
| | Inflammation Markers, Adhesion Molecules, and All-Cause and Cardiovascular Mortality in Patients with ESRD: Searching for the Best Risk Marker by Multivariate Modeling | Q58950000 |
| | Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin | Q59319205 |
| P433 | issue | 4 | |
| P921 | main subject | kidney disease | Q1054718 |
| P304 | page(s) | 335-341 | |
| P577 | publication date | 2006-03-23 | |
| P1433 | published in | Blood Purification | Q15759923 |
| P1476 | title | The predictive value of C-reactive protein in end-stage renal disease: is it clinically significant? | |
| P478 | volume | 24 | |